Literature DB >> 2902317

Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function.

P W Mathieson1, A N Turner, C G Maidment, D J Evans, A J Rees.   

Abstract

Eight patients with idiopathic membranous nephropathy whose renal function was deteriorating were given a 6-month course of alternating monthly cycles of prednisolone and chlorambucil. Proteinuria was reduced in all eight, from a mean (SD) of 15.3 (5.9) g/24 h at the start of treatment to 2.1 (1.5) g/24 h at follow-up (p less than 0.05). Creatinine clearance increased in six, and the rate of decline was reduced in the other two (group mean 51.6 [17.8] ml/min at the start of treatment and 81.4 [36.8] ml/min at follow-up; p less than 0.05). Adverse effects of chlorambucil were severe, and the daily dose had to be reduced. Prednisolone and chlorambucil treatment can change the natural course of membranous nephropathy even when renal function has started to deteriorate, so treatment can be reserved for high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902317     DOI: 10.1016/s0140-6736(88)92470-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Crescentic transformation in primary membranous glomerulonephritis.

Authors:  J T Kwan; R H Moore; S M Dodd; J Cunningham
Journal:  Postgrad Med J       Date:  1991-06       Impact factor: 2.401

Review 2.  Current treatment recommendations for lupus nephritis.

Authors:  C Ponticelli
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 3.  Membranous nephropathy in childhood and its treatment.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 4.  Autoimmunity and the pathogenesis of glomerulonephritis.

Authors:  D B Oliveira; D K Peters
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

5.  Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis.

Authors:  R Brunkhorst; E Wrenger; K M Koch
Journal:  Clin Investig       Date:  1994-03

Review 6.  Glomerular diseases: membranous nephropathy--a modern view.

Authors:  Claudio Ponticelli; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 8.237

Review 7.  Idiopathic membranous nephropathy: management strategies.

Authors:  Marco Quaglia; Piero Stratta
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

Review 8.  Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.

Authors:  Francesco Scolari; Federico Alberici; Federica Mescia; Elisa Delbarba; Hernando Trujillo; Manuel Praga; Claudio Ponticelli
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

9.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.

Authors:  Andrew Howman; Tracey L Chapman; Maria M Langdon; Caroline Ferguson; Dwomoa Adu; John Feehally; Gillian J Gaskin; David R W Jayne; Donal O'Donoghue; Michael Boulton-Jones; Peter W Mathieson
Journal:  Lancet       Date:  2013-01-09       Impact factor: 79.321

10.  Chapter 7: Idiopathic membranous nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.